RxDoctor Payments Data

Dominick Stella, MD

Interventional Cardiology · Palos Park, ILNPI 1932163623

Payments from drug & device makers

$10,184in general payments, 2019–2025

Across 562 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$1K
  • Medtronic$988
  • Pfizer$737
  • Novo Nordisk$509
  • Amgen$507
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$10,06299%
  • Education$1221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,184 in reported general payments places this provider in the 50th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$548,002
Medicare patients
2,617
Services billed
29,069

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban242$325,588
XareltoRivaroxaban56$77,837
EntrestoSacubitril/Valsartan44$61,313
Nisoldipine127$52,456
BrilintaTicagrelor25$18,707
Rosuvastatin Calcium917$14,285
FarxigaDapagliflozin Propanediol11$12,055
Atorvastatin Calcium727$8,710
Metoprolol Succinate435$7,965
Ezetimibe282$6,923
Lisinopril544$6,830
Metoprolol Tartrate433$4,176
Losartan Potassium351$3,744
ClopidogrelClopidogrel Bisulfate276$3,309
Amlodipine Besylate393$3,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$737$325,588242 claims
Johnson & JohnsonXarelto$1,077$77,83756 claims
NovartisEntresto$1,325$61,31344 claims
AstraZenecaBrilinta, Farxiga$485$30,76236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Palos Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →